Results

Total Results: 463 records

Showing results for "renal".

121. Gout Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/gout_executive.pdf
     March 01, 2016 - Both colchicine and NSAIDs require dose reduction in renal impairment. … Allopurinol treatment and its effect on renal function in gout: a controlled study. … Description and guidelines for prevention in patients with renal insufficiency. … Allopurinol-induced severe hypersensitivity with acute renal failure. … Allopurinol, erythema multiforme, and renal insufficiency. BMJ. 1996 Jan 20;312(7024):173-4.

122. pneumonia-antibiotic-treatment-protocol-130718 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/pneumonia-antibiotic-treatment_research-protocol.pdf
     July 19, 2013 - empiric antibiotic-dosing regimens are based on data from noncritically ill patients (with or without renal … with new data derived from patients with HAP, including those who are critically ill with or without renal … Based on public comments, we have added renal dysfunction as a subgroup in KQ 3. … Subgroups:   • HAP, VAP, and HCAP • Immunocompromised • Age, sex, race, and ethnicity • Renal … Roberts DM, Roberts JA, Roberts MS, et al; RENAL Replacement Therapy Study Investigators.

123. Topic Brief: Patient Activation in Chronic Kidney Disease (pdf file)
     effectivehealthcare.ahrq.gov/system/files/docs/topic-brief-chronic-kidney-disease.pdf
     June 01, 2021 - Issue: Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are prevalent and require significant … Chronic kidney disease can progress to kidney failure, also known as end-stage renal disease (ESRD). … Search strategy "renal insufficiency, chronic"[MeSH Terms] OR "chronic kidney disease"[All Fields] OR … Abbreviations: AHRQ=Agency for Healthcare Research and Quality; CKD=chronic kidney disease; ESRD=end- stage renal

124. Diabetes Medications for Adults with Type 2 Diabetes: An Update Focused on Monotherapy and Add-on Therapy to Metformin | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/diabetes-update-2015/research-protocol
     January 22, 2015 - The inclusion of the safety outcomes of impaired renal function, urinary tract infections, genital mycotic … outcome. 2 A meta-analysis published in 2013, 18 and data from pivotal trials 19,20 have suggested that renal … at least one of the following comorbid conditions: End-stage liver disease or cirrhosis End-stage renal … PICOTS Inclusion criteria Exclusion criteria ESLD = end-stage liver disease; ESRD = end-stage renal … We will include studies addressing the following safety outcomes for KQ3: Liver injury ^ Impaired renal

125. Pharmacokinetic/Pharmacodynamic Measures for Guiding Antibiotic Treatment for Nosocomial Pneumonia | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/pneumonia-antibiotic-treatment/research-protocol
     July 19, 2013 - dosing, concurrent nephrotoxic drugs, or prolonged courses of therapy and or in patients with unstable renal … empiric antibiotic-dosing regimens are based on data from noncritically ill patients (with or without renal … with new data derived from patients with HAP, including those who are critically ill with or without renal … Based on public comments, we have added renal dysfunction as a subgroup in KQ 3. … Roberts DM, Roberts JA, Roberts MS, et al; RENAL Replacement Therapy Study Investigators.

126. Kidney-Stone-Prevention Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-stone-prevention_executive.pdf
     March 01, 2013 - Renal stone epidemiology in Rochester, Minnesota: an update. … Kairaitis L, Caring for Australians with Renal I. The CARI guidelines. … Becker G, Caring for Australians with Renal I. The CARI guidelines. Kidney stones: cystine stones. … Becker G, Caring for Australians with Renal I. The CARI guidelines. … Placebo versus allopurinol for renal calculi. Journal of Urology. 1977 Jun;117(6):690-2.

127. Bladder-Cancer-Muscle-Invasive Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/bladder-cancer-muscle-invasive_executive.pdf
     June 01, 2015 - Therefore, factors such as performance status and renal function must be considered in relation to treatment … For example, medically frail patients with baseline renal insufficiency may not be ideal candidates … for cisplatin-based therapy because of potential renal toxicity. … Although cisplatin is nephrotoxic, renal adverse events were not well reported.28 No study compared … For patients with renal dysfunction, carboplatin may be considered because it is less nephrotoxic than

128. Future Research Needs for Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRIs) for Treating Hypertension (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/ace-inhibitor-arb-future_research.pdf
     March 01, 2012 - Advances in antihypertensive therapy have dramatically reduced cardiovascular, cerebrovascular, and renal … intake on ACEI/ARB/DRI effectiveness or harms . 3 The impact of ACEI/ARB/DRI on progression of renal … Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes … There appears to be a small difference in change in renal function between ACE inhibitors and ARBs ( … Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2

129. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/plasma-cell-dyscrasias-sflc-assay_research-protocol.pdf
     May 02, 2011 - marrow plasma cells ≤10%  Absence of end-organ damage (bone lesions, anemia, hypercalcemia, or renal … urinary monoclonal protein  Evidence of end-organ damage (bone lesions, anemia, hypercalcemia, or renal … marrow plasma cells ≥10%  Absence of end-organ damage (bone lesions, anemia, hypercalcemia, or renal … end-organ damage, including skeletal destruction (lytic bone lesions), hypercalcemia, anemia, and renal … This ratio remains normal in polyclonal hypergammaglobulinemia or in renal insufficiency where free

130. Enzyme-Replacement Therapies for Lysosomal Storage Diseases | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/lysosomal-storage-diseases-therapies/technical-brief
     January 02, 2013 - common hematological measures (e.g., anemia, thrombocytopenia), bone pain and skeletal abnormalities, renal

131. Santa_ECCS2012 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/santa_eccs2012.pdf
     February 01, 2013 - Plain-­‐language versions of selected topics • Longer “stories” about more complex topics: chronic renal … Cancer (American Society of Clinical Oncology): “Even in cancer, more may not be better.” • Chronic  renal … failure (American Society of Nephrology): “Even in chronic renal disease, more treatment may not be

132. Research Protocol: Diabetes Medications for Adults With Type 2 Diabetes: An Update Focused on Monotherapy and Add-On Therapy to Metformin (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-update-2015_research-protocol.pdf
     January 01, 2015 - • The inclusion of the safety outcomes of impaired renal function, urinary tract infections, genital … side effects; and for comparisons including SGLT-2 inhibitors, urinary tract infections, impaired renal … side effects; and for comparisons including SGLT-2 inhibitors, urinary tract infections, impaired renal … one of the following comorbid conditions: • End-stage liver disease or cirrhosis • End-stage renal … include studies addressing the following safety outcomes for KQ3: § Liver injury^ § Impaired renal

133. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0430_04-22-2011.pdf
     January 01, 2011 - recatheterization, prevention of urinary tract infections, improved quality of life, potential harms (infection, renal

134. Diagnosis of Gout | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/gout/research-protocol-2014
     July 17, 2014 - hypertriglyceridemia, hypercholesterolemia, type 2 diabetes and metabolic syndrome, chronic kidney disease, and renal … Hyperuricemia can be the result of either inadequate renal excretion of UA or, less commonly, UA overproduction … of gout are multifactorial, including a combination of genetic, hormonal, metabolic, pharmacologic, renal … younger patients Patients with comorbidities including hypertension, type 2 diabetes, kidney disease (renal … analysis will be conducted by age group and particular comorbidities, such as hypertension, type 2 DM, or renal

135. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cad-women-treatment_research-protocol.pdf
     September 29, 2011 - each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal … effects of intervention(s): Adverse drug reactions, radiation exposure, access site complications, renal … life Cognitive effects Adverse drug reactions, radiation exposure, access site complications, renal … adverse effects, including adverse drug reactions, radiation exposure, access-site complications, renal … adverse events, including adverse drug reactions, radiation exposure, access-site complications, renal

136. Stroke Prevention in Atrial Fibrillation Patients: A Systematic Review Update | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/stroke-afib-update/research-protocol
     July 07, 2017 - The HAS-BLED (H=hypertension, A=abnormal renal/liver function, S=stroke, B=bleeding history or predisposition … inhibitor; DVT = deep vein thrombosis; eGFR = estimated glomerular filtration rate; ESRD = end-stage renal … , labile INR, elderly (> 65), drugs/alcohol concomitantly; HEMORR2HAGES = hepatic or renal disease, ethanol … failure"[tiab] OR "end stage renal disease"[tiab] OR ESRD[tiab] OR “end stage kidney disease”[tiab] … OR ESKD[tiab] OR “renal function”[tiab] OR diabetes[tiab] OR diabetic[tiab] OR sex[tiab] OR race[tiab

137. Topic Suggestion Description | Effective Health Care Program
     effectivehealthcare.ahrq.gov/get-involved/nominated-topics/chronic-kidney-disease
     December 02, 2020 - With the rapid growth in the number of Americans who face chronic kidney disease (CKD) and end-stage renal

138. Gout Dx protocol_140715-draft (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/gout_research-protocol-2014.pdf
     January 01, 2014 - hypertriglyceridemia, hypercholesterolemia, type 2 diabetes and metabolic syndrome, chronic kidney disease, and renal … Hyperuricemia can be the result of either inadequate renal excretion of UA or, less commonly, UA overproduction … of gout are multifactorial, including a combination of genetic, hormonal, metabolic, pharmacologic, renal … Patients with comorbidities including hypertension, type 2 diabetes, kidney disease (renal insufficiency … analysis will be conducted by age group and particular comorbidities, such as hypertension, type 2 DM, or renal

139. Clinical Effectiveness of Coronary Stents in the Elderly: Results From 262,700 Patients in the American College of Cardiology-National Cardiovascular Data Registry | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/coronary-stents-outcomes/research
     February 10, 2010 - with DES plus a selected group of clinically important variables including: gender, age, diabetes, renal … As expected, mortality was higher in those with diabetes, renal failure, STEMI or CHF. … This effect was somewhat less pronounced in those with a prior history of CABG and renal failure, with … Similarly, the 30-month risk of MI was lower in all patient subgroups except those with renal failure … (Figure 4c) However, no benefit was observed in patients >75 years, or with diabetes, renal failure,

140. Untitled (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-disease-ace-inhibitor-arb_surveillance.pdf
     July 06, 2015 - presence and pattern of symptoms), dose of the ACE inhibitor or ARB used, comorbidities (diabetes, renal … Worsening renal function and outcome in heart failure patients with preserved ejection fraction and … presence and pattern of symptoms), dose of the ACE inhibitor or ARB used, comorbidities (diabetes, renal … In TRANSCEND trial, ARB vs. placebo was associated with a higher rate of renal events for patients with … However, in patients with microalbuminuria, the rate of renal events was not significantly different